Evidence map›Paper›PMID 41815740›Full record

ArticleRespirology case reports2026

Amivantamab Monotherapy for Lung Adenocarcinoma With Leptomeningeal Seeding: A Case Report.

Kyeoungseo Park, So Yeon Kim, Sang-Won Um

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kyeoungseo ParkDepartment of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea.ORCID https://orcid.org/0009-0002-2688-7271
So Yeon KimDivision of Pulmonary and Critical Care Medicine, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea.
Sang-Won UmDivision of Pulmonary and Critical Care Medicine, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea.ORCID https://orcid.org/0000-0002-9765-9068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is characterised by a number of driver mutations, among which epidermal growth factor receptor (EGFR) exon 20 insertion mutations are associated with poor prognosis due to structural alterations that confer resistance to conventional tyrosine kinase inhibitors (TKIs). Recently, amivantamab, a fully human bispecific antibody targeting EGFR and MET, has demonstrated promising efficacy in patients with EGFR exon 20 insertion mutations. However, its therapeutic activity against central nervous system metastases remains uncertain. Here, we report a case of a patient with NSCLC who developed leptomeningeal seeding (LMS) after the failure of first-line therapy and showed a marked clinical and radiologic response to amivantamab monotherapy.

Indexed as

amivantamabepidermal growth factor receptor (EGFR) exon 20 insertionleptomeningeal seeding (LMS)non‐small cell lung cancer (NSCLC)tyrosine kinase inhibitor (TKI)

Identifiers

PMID41815740
PMCPMC12971247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.